Cost-effectiveness of novel antiandrogens for the treatment of nmCRPC patients in the Chinese healthcare system
Therapeutic Advances in Urology
Published online on January 28, 2026
Abstract
Therapeutic Advances in Urology, Volume 18, January-December 2026.
Background:Novel androgen receptor inhibitors (ARIs) have been recommended for patients with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).Objective:The present study aims to evaluate the cost-effectiveness of darolutamide, ...
Background:Novel androgen receptor inhibitors (ARIs) have been recommended for patients with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).Objective:The present study aims to evaluate the cost-effectiveness of darolutamide, ...